Publication:
Is It Justifiable to Move the Grade-1 Ki67 Index Cut-Off from 3% to 5% for Pancreatic Neuroendocrine Tumors as Has Been Proposed? The Cases That Fall to 3-5% Category Have Clinicopathologic Characteristics Closer to Those > 5%

Simple item page
dc.contributor.authorsReid, Michelle; Balci, Serdar; Bagci, Pelin; Saka, Burcu; Pehlivanoglu, Burcin; Seven, Ipek Erbarut; Basturk, Olca; Adsay, N. Volkan
dc.date.accessioned2022-03-12T16:24:43Z
dc.date.accessioned2026-01-10T16:54:34Z
dc.date.available2022-03-12T16:24:43Z
dc.date.issued2020
dc.identifier.doidoiWOS:000518328903466
dc.identifier.eissn1530-0285
dc.identifier.issn0893-3952
dc.identifier.urihttps://hdl.handle.net/11424/226434
dc.identifier.wosWOS:000518328903466
dc.language.isoeng
dc.publisherSPRINGERNATURE
dc.relation.ispartofMODERN PATHOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.titleIs It Justifiable to Move the Grade-1 Ki67 Index Cut-Off from 3% to 5% for Pancreatic Neuroendocrine Tumors as Has Been Proposed? The Cases That Fall to 3-5% Category Have Clinicopathologic Characteristics Closer to Those > 5%
dc.typeconferenceObject
dspace.entity.typePublication
oaire.citation.endPage1673
oaire.citation.issueSUPPL 2
oaire.citation.startPage1673
oaire.citation.titleMODERN PATHOLOGY
oaire.citation.volume33

Files

Collections

Araştırma Çıktıları